Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint

A phase 3 study of Otsuka and Ionis Pharmaceuticals’ amyotrophic lateral sclerosis drug candidate has hit its primary endpoint, positioning the partners to talk to regulators about expedited approvals.